Latest Insider Transactions at Poseida Therapeutics, Inc. (PSTX)
This section provides a real-time view of insider transactions for Poseida Therapeutics, Inc. (PSTX). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Poseida Therapeutics, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Poseida Therapeutics, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Dec 10
2024
|
Mark J Gergen Executive Chairman |
SELL
Open market or private sale
|
Direct |
30,000
-4.4%
|
$270,000
$9.46 P/Share
|
|
Dec 10
2024
|
Mark J Gergen Executive Chairman |
BUY
Exercise of conversion of derivative security
|
Direct |
30,000
+4.22%
|
$60,000
$2.78 P/Share
|
|
Nov 26
2024
|
Mark J Gergen Executive Chairman |
SELL
Open market or private sale
|
Direct |
30,000
-4.4%
|
$270,000
$9.27 P/Share
|
|
Nov 26
2024
|
Mark J Gergen Executive Chairman |
BUY
Exercise of conversion of derivative security
|
Direct |
30,000
+4.22%
|
$60,000
$2.78 P/Share
|
|
Jun 17
2024
|
Luke Corning |
BUY
Grant, award, or other acquisition
|
Direct |
19,650
+25.0%
|
-
|
|
Jun 17
2024
|
Marcea Bland Lloyd |
BUY
Grant, award, or other acquisition
|
Direct |
19,650
+22.18%
|
-
|
|
Jun 17
2024
|
John P. Schmid |
BUY
Grant, award, or other acquisition
|
Direct |
19,650
+25.0%
|
-
|
|
Jun 17
2024
|
Rafael Amado |
BUY
Grant, award, or other acquisition
|
Direct |
19,650
+25.0%
|
-
|
|
Jun 17
2024
|
Charles M Baum |
BUY
Grant, award, or other acquisition
|
Direct |
19,650
+20.0%
|
-
|
|
Jun 17
2024
|
Cynthia Collins |
BUY
Grant, award, or other acquisition
|
Direct |
19,650
+25.0%
|
-
|
|
Apr 01
2024
|
Syed Ali Aamir Rizvi Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
185,000
+50.0%
|
-
|
|
Mar 01
2024
|
Johanna Mylet Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
18,091
-6.84%
|
$72,364
$4.13 P/Share
|
|
Mar 01
2024
|
Johanna Mylet Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
80,743
+23.4%
|
-
|
|
Mar 01
2024
|
Brent Warner President, Gene Therapy |
SELL
Payment of exercise price or tax liability
|
Direct |
35,739
-7.86%
|
$142,956
$4.13 P/Share
|
|
Mar 01
2024
|
Brent Warner President, Gene Therapy |
BUY
Grant, award, or other acquisition
|
Direct |
80,743
+15.08%
|
-
|
|
Mar 01
2024
|
Harry J Leonhardt GC & Chief Compliance Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
16,306
-7.06%
|
$65,224
$4.13 P/Share
|
|
Mar 01
2024
|
Harry J Leonhardt GC & Chief Compliance Officer |
BUY
Grant, award, or other acquisition
|
Direct |
80,743
+25.91%
|
-
|
|
Mar 01
2024
|
Mark J Gergen Executive Chairman |
SELL
Payment of exercise price or tax liability
|
Direct |
34,157
-4.98%
|
$136,628
$4.13 P/Share
|
|
Feb 01
2024
|
Mark J Gergen Executive Chairman |
SELL
Payment of exercise price or tax liability
|
Direct |
47,162
-6.44%
|
$141,486
$3.41 P/Share
|
|
Jan 02
2024
|
Mark J Gergen Executive Chairman |
BUY
Grant, award, or other acquisition
|
Direct |
125,000
+14.58%
|
-
|
|
Jan 02
2024
|
Kristin Yarema President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
250,000
+29.18%
|
-
|
|
Jun 15
2023
|
Marcea Bland Lloyd |
BUY
Grant, award, or other acquisition
|
Direct |
19,650
+28.5%
|
-
|
|
Jun 15
2023
|
John P. Schmid |
BUY
Grant, award, or other acquisition
|
Direct |
19,650
+33.33%
|
-
|
|
Jun 15
2023
|
Cynthia Collins |
BUY
Grant, award, or other acquisition
|
Direct |
19,650
+33.33%
|
-
|
|
Jun 15
2023
|
Luke Corning |
BUY
Grant, award, or other acquisition
|
Direct |
19,650
+33.33%
|
-
|
|
Jun 15
2023
|
Charles M Baum |
BUY
Grant, award, or other acquisition
|
Direct |
19,650
+25.0%
|
-
|
|
May 01
2023
|
Rafael Amado |
BUY
Grant, award, or other acquisition
|
Direct |
39,300
+50.0%
|
-
|
|
Apr 11
2023
|
Kristin Yarema President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
356,836
+50.0%
|
-
|
|
Mar 01
2023
|
Brent Warner President, Gene Therapy |
SELL
Payment of exercise price or tax liability
|
Direct |
26,617
-6.64%
|
$133,085
$5.35 P/Share
|
|
Mar 01
2023
|
Brent Warner President, Gene Therapy |
BUY
Grant, award, or other acquisition
|
Direct |
92,772
+18.8%
|
-
|
|
Mar 01
2023
|
Harry J Leonhardt GC & Chief Compliance Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
4,323
-2.91%
|
$21,615
$5.35 P/Share
|
|
Mar 01
2023
|
Harry J Leonhardt GC & Chief Compliance Officer |
BUY
Grant, award, or other acquisition
|
Direct |
92,772
+38.45%
|
-
|
|
Mar 01
2023
|
Johanna Mylet Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
4,323
-2.38%
|
$21,615
$5.35 P/Share
|
|
Mar 01
2023
|
Johanna Mylet Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
92,772
+33.77%
|
-
|
|
Mar 01
2023
|
Mark J Gergen Executive Chairman |
BUY
Grant, award, or other acquisition
|
Direct |
269,586
+30.94%
|
-
|
|
Feb 01
2023
|
Mark J Gergen Executive Chairman |
SELL
Payment of exercise price or tax liability
|
Direct |
31,819
-8.79%
|
$222,733
$7.0 P/Share
|
|
Feb 01
2023
|
Eric Ostertag Director |
SELL
Payment of exercise price or tax liability
|
Direct |
11,776
-1.4%
|
$82,432
$7.0 P/Share
|
|
Aug 08
2022
|
Eric Ostertag Director |
BUY
Open market or private purchase
|
Direct |
142,857
+14.55%
|
$428,571
$3.5 P/Share
|
|
Aug 08
2022
|
Malin Life Sciences Holdings LTD > 10% Shareholder |
BUY
Open market or private purchase
|
Direct |
2,150,000
+15.37%
|
$6,450,000
$3.5 P/Share
|
|
Aug 03
2022
|
Eric Ostertag Director |
SELL
Open market or private sale
|
Indirect |
160,696
-100.0%
|
$482,088
$3.69 P/Share
|
|
Jun 16
2022
|
Cynthia Collins |
BUY
Grant, award, or other acquisition
|
Direct |
19,650
+50.0%
|
-
|
|
Jun 16
2022
|
Marcea Bland Lloyd |
BUY
Grant, award, or other acquisition
|
Direct |
19,650
+39.86%
|
-
|
|
Jun 16
2022
|
John P. Schmid |
BUY
Grant, award, or other acquisition
|
Direct |
19,650
+50.0%
|
-
|
|
Jun 16
2022
|
Luke Corning |
BUY
Grant, award, or other acquisition
|
Direct |
19,650
+50.0%
|
-
|
|
Jun 16
2022
|
Charles M Baum |
BUY
Grant, award, or other acquisition
|
Direct |
39,300
+50.0%
|
-
|
|
Mar 16
2022
|
Kerry D. Ingalls Chief Operating Officer |
BUY
Open market or private purchase
|
Direct |
3,000
+5.17%
|
$9,000
$3.98 P/Share
|
|
Mar 01
2022
|
Brent Warner President, Gene Therapy |
BUY
Grant, award, or other acquisition
|
Direct |
307,881
+50.0%
|
-
|
|
Mar 01
2022
|
Matthew A. Spear Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
50,000
+30.96%
|
-
|
|
Mar 01
2022
|
Johanna Mylet Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
50,000
+37.25%
|
-
|
|
Mar 01
2022
|
Kerry D. Ingalls Chief Operating Officer |
BUY
Grant, award, or other acquisition
|
Direct |
50,000
+49.02%
|
-
|